RT Journal Article
T1 First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort.
A1 Ruiz-Irastorza, G
A1 Garcia, M
A1 Espinosa, G
A1 Caminal, L
A1 Mitjavila, F
A1 González-León, R
A1 Sopeña, B
A1 Canora, J
A1 Villalba, M V
A1 Rodríguez-Carballeira, M
A1 López-Dupla, J M
A1 Callejas, J L
A1 Castro, A
A1 Tolosa, C
A1 Sánchez-García, M E
A1 Pérez-Conesa, M
A1 Navarrete-Navarrete, N
A1 Rodríguez, A P
A1 Herranz, M T
A1 Pallarés, L
K1 Antimaláricos
K1 Glucocorticoides
K1 Humanos
K1 Inmunosupresores
K1 Lupus eritematoso discoide
K1 Lupus eritematoso sistémico
K1 Nefritis lúpica
K1 Metilprednisolona
K1 Prednisona
K1 Pulso arterial
AB AIMTo study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2-12).METHODS223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2-12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2-12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2-12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI).RESULTSWithin the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2-12 dose categories (p<0.001). The cumulative prednisone-1 dose was directly associated with the cumulative prednisone-2-12 dose (p<0.001). Compared with patients on no prednisone, patients taking medium (adjusted OR 5.27, 95% CI 2.18 to 12.73) or high-dose prednisone-1 (adjusted OR 10.5, 95% CI 3.8 to 29.17) were more likely to receive prednisone-2-12 doses of >7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of ≥6, the model did not change.CONCLUSIONThe dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months.
PB BMJ Publishing Group
YR 2016
FD 2016-08-16
LK http://hdl.handle.net/10668/2498
UL http://hdl.handle.net/10668/2498
LA en
NO Ruiz-Irastorza G, Garcia M, Espinosa G, Caminal L, Mitjavila F, González-León R, et al. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med. 2016; 3(1):e000153
NO Journal Article;
DS RISalud
RD Apr 12, 2025